Financial Information
Expected Liquidity & Strategic Measures
The Company’s operational financing plan does not require any additional external financing to fund organic growth in the medium term. However, any strategic moves to further push growth and strengthen the Company’s competitive position or increase critical mass via potential company or product acquisitions, equity investments or extended R&D efforts will need to be considered separately. Evotec intends to achieve significant organic capacity growth as a result of its corporate strategy. The Company continued to increase investments in the expansion and development of individual locations in 2023. In Toulouse, it has started to significantly expand its capacities and to build J.POD Toulouse, France. Moreover, it is expanding the existing campus in Abingdon, Oxfordshire, UK, and construction of the new building for the planned iPSC centre in Hamburg has progressed significantly. After the completion of the first J.POD facility in North America, the Company expects the completion of the second J.POD facility in Toulouse, France in 2024. The two J.POD facilities meet the production requirements of the coming years and strengthen Evotec's position as a leading partner for drug discovery and development with revolutionary technologies.